Shopping Cart
Remove All
Your shopping cart is currently empty
Ecleralimab is a potent inhaled antibody fragment (scFv) targeting TSLP, acting by blocking the binding of TSLP to its receptor complex. The compound is an essential tool for investigating the role of airway epithelial-derived cytokines in asthma pathogenesis, aiming to alleviate Type 2 inflammatory responses by inhibiting the upstream immune cascade.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $290 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $763 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,230 | 2-4 weeks | 2-4 weeks |
| Description | Ecleralimab is a potent inhaled antibody fragment (scFv) targeting TSLP, acting by blocking the binding of TSLP to its receptor complex. The compound is an essential tool for investigating the role of airway epithelial-derived cytokines in asthma pathogenesis, aiming to alleviate Type 2 inflammatory responses by inhibiting the upstream immune cascade. |
| Synonyms | NVP-CSJ117, CSJ-117 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | TSLP |
| Cas No. | 2415207-91-7 |
| Isotype | IgG1-KR-EPKSC |
| Storage | Lyophilized powder: -20~-80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.